Circulating tumor cells are important biomarkers for understanding a patient's cancer. They have not been widely adopted in the clinic or in drug development because previous technologies had 2 key limitations. 1) Not enough patients were found to have cells. 2) Captured cells were not viable for downstream ‘omics analysis. StrandSmart has developed a unique platform that captures cells in a majority of patients, and preserves the cells for downstream analysis that unlocking key data to inform clinical decision-making, as well as guides drug development.